The latest biotech news

Inventiva fibrosis abbvie boehringer ingelheim

News and Trends 5 Sep 2017

French Biotech Lures Big Pharma with Fibrosis Treatments

This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

AMAL Therapeutics Cancer Vaccine Series B

News and Trends 5 Sep 2017

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […]

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

destiny pharma new antibiotics mrsa london stock1

News and Trends 4 Sep 2017

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Destiny Pharma has started trading on the London Stock Exchange to support its search for new antibiotics that can fight resistant bacteria like MRSA. Destiny Pharma, based in Brighton, UK, has entered the AIM market of the London Stock Exchange with an initial placement of £15.3M (€16.7M), which put its starting market cap at £65.4M […]

September 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Sep 2017

Record Momentum for European Biotech

The European biotech sector has had a bumpy past. Today, however it has reached a record momentum and is flourishing like never before. Stock exchanges, such as Euronext, support Biotech companies and have contributed largely to the record high we see today. The global financial crisis hit Europe in 2008. Like a tidal wave, it […]

September 4, 2017 - 10 minutesmins - By External Contributor

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

CAR T cell therapy FDA approval cancer Novartis Kymriah CTL019

News and Trends 31 Aug 2017

The FDA Approves the First CAR-T Cell Therapy for Cancer

The FDA has approved Novartis’ CAR-T therapy Kymriah, opening the way for a new generation of cell therapy treatments against cancer. Novartis’ Kymriah (tisagenlecleucel), formerly known as CTL019, has become the first gene-modified cell therapy approved in the US. The FDA has approved the therapy for relapsing B-cell acute lymphoblastic leukemia (ALL) in children and young […]

August 31, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

probiodrug alzheimers disease mechanism of action

News and Trends 30 Aug 2017

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is developing a therapeutic antibody with a unique mode of action against Alzheimer’s, PBD-C06. The company announced yesterday the publication in the Journal of Biological Chemistry of the detailed binding […]

August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Aug 2017

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter the final leg of the race to launch the first CAR-T therapy, a technology that is expected to change how cancer is treated. Despite the technology’s […]

August 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Apeiron biologics eib efsi funding neuroblastoma

News and Trends 28 Aug 2017

Austrian Biotech Gets €25M of EU Funding to Fight Rare Childhood Cancer

Apeiron Biologics has been granted financing of €25M from the European Investment Bank (EIB) to support the development of new treatments for cancer. Apeiron Biologics is a biotech based in Vienna focused on developing immuno-oncology treatments designed to make the immune system attack cancer cells. The EIB has decided to support the company’s research of a […]

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

samsung bioepis imraldi humira adalimumab biosimilar tnf a

News and Trends 28 Aug 2017

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie’s Humira (adalimumab), which has topped revenue charts for years. Samsung Bioepis’ Imraldi has now marketing authorization in the EU as a biosimilar of Humira (adalimumab) for the treatment of over 10 inflammatory indications, including rheumatoid arthritis, psoriasis, Crohn’s disease and ulcerative colitis. This makes […]

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Aug 2017

Merck Ventures Joins Series A of Brisith Biotech Using Macrophages to Fight Cancer

Merck Ventures has joined the team of investors behind Macrophage Pharma, a biotech in Windsor, UK, using macrophages against cancer. Macrophage Pharma is a young biotech working on a new approach to boost the immune system’s ability to attack tumor cells. Its technology attracted £9M (€9.8M) in Series A earlier this year from the CRT Pioneer […]

August 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

French Biotech Lures Big Pharma with Fibrosis Treatments

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Record Momentum for European Biotech

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

The FDA Approves the First CAR-T Cell Therapy for Cancer

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

Austrian Biotech Gets €25M of EU Funding to Fight Rare Childhood Cancer

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Merck Ventures Joins Series A of Brisith Biotech Using Macrophages to Fight Cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!